No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.3x · 10Y median 4.0x · 13th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:28:37.321Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Treace Medical Concepts, Inc. (TMCI) stock was $4.17 as of Oct 6, 2026, 2:24 PM EDT, down 7.03% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -29.4% · 3-year avg -28.6%/yr · 5-year avg -29.4%/yr
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Medical - Devices · Ponte Vedra, FL
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.26
Revenue Est.
$47.71M
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.30
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TMCI | $270.20M | $4.17 | -7.03% | -29.44% | -29.41% | N/A | N/A |
| 2TLSI | $270.00M | $4.38 | +0.11% | -5.17% | -15.05% | N/A | vs TMCI |
| 3SABS | $270.41M | $2.97 | -4.13% | +50.19% | -50.16% | N/A | vs TMCI |
| 4VNDA | $270.61M | $4.50 | -1.75% | -15.59% | -23.91% | -11.90% | vs TMCI |
| 5SCTX | $269.43M | $16.65 | +2.71% | N/A | N/A | N/A | vs TMCI |
| 6FATE | $271.00M | $2.33 | -4.32% | +100.16% | -46.86% | -2.31% | vs TMCI |
forward FY estimate
N/A
$45.38M
vs Estimate
$44.02M
Consensus Rating
Based on 3 analysts
Average Price Target
$5.50
+32.1% upside
Low
$4.50
Current
$4.17
High
$7.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.25 | $-0.25 | $-0.24 | 1 |
| Quarter ending Dec 2026 | $-0.07 | $-0.07 | $-0.06 | 1 |
| Quarter ending Mar 2027 | $-0.25 | $-0.25 | $-0.24 | 1 |
| Quarter ending Jun 2027 | $-0.24 | $-0.24 | $-0.23 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.87 | $-0.85 | $-0.84 | 4 |
| FY 2027 | $-0.85 | $-0.77 | $-0.69 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $47.60M | $47.71M | $47.82M | 3 |
| Quarter ending Dec 2026 | $67.23M | $67.31M | $67.38M | 3 |
| Quarter ending Mar 2027 | $51.14M | $51.48M | $51.77M | 1 |
| Quarter ending Jun 2027 | $48.74M | $49.07M | $49.34M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $207.43M | $207.48M | $207.52M | 4 |
| FY 2027 | $221.24M | $221.68M | $222.11M | 4 |
